2022 Annual Meeting | C75 - Neuro-oncology: Navigating Current Trends

Date Monday 04/04/22

Time 01:00 PM - 03:00 PM PDT Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program will be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Maciej M. Mrugala, MD, PhD, MPH, F�鶹��ýӳ��

Topic(s) Neuro-oncology

Learning Objectives The learners will be able to acquire knowledge on the new WHO CNS tumors classification. New targeted therapies available to a neuro-oncologist will be discussed in detail. The faculty will cover both primary and metastatic brain tumors. Recent FDA-approved agents for the treatment of NF1 associated plexiform neurofibromas, as well as Von-Hipple Lindau disease-associated tumors, will be discussed.

CME Available 2.00 CME credits

Core Competencies Patient Care & Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement

Program Level Intermediate

Recommended Audience Fellow, Resident, General Neurologist, Specialist Neurologist, Advanced Practice Provider, Neurohospitalist

Teaching Styles Case-based, Didactic

Program Materials Program Evaluations

Event Timeline
01:00 PM - 01:05 PM PDT	Introduction	Introduction Maciej M. Mrugala, MD, PhD, MPH, F�鶹��ýӳ��
01:00 PM - 01:00 PM PDT	Speaker	walk in slides Maciej M. Mrugala, MD, PhD, MPH, F�鶹��ýӳ��
01:05 PM - 01:40 PM PDT	Speaker	Contemporary Approach to Metastatic Disease in the CNS Wendy Sherman, MD
01:40 PM - 02:20 PM PDT	Speaker	Deeper Dive into WHO CNS5 Classification with Practical Implications for a Neuro-oncologist Craig Horbinski, MD
02:20 PM - 02:40 PM PDT	Speaker	Targeted Therapy in Neuro-oncology Clinic - Expanding Menu of Options Maciej M. Mrugala, MD, PhD, MPH, F�鶹��ýӳ��
02:40 PM - 03:00 PM PDT	Discussion	Discussion & Questions and Answers Maciej M. Mrugala, MD, PhD, MPH, F�鶹��ýӳ��, Craig Horbinski, MD, Wendy Sherman, MD

Faculty Disclosures
Maciej M. Mrugala, MD, PhD, MPH, F�鶹��ýӳ��	Dr. Mrugala has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Veevo Biomedicines Inc. Dr. Mrugala has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Arbor Pharmaceuticals. Dr. Mrugala has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Astra-Zeneca. Dr. Mrugala has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Servier. Dr. Mrugala has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Medscape. Dr. Mrugala has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Mrugala has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Kyiatec . The institution of Dr. Mrugala has received research support from Arbor Pharmaceuticals. Dr. Mrugala has a non-compensated relationship as a Program Director with Society for Neuro-Oncology that is relevant to �鶹��ýӳ�� interests or activities.
Craig Horbinski, MD	Craig Horbinski, MD has nothing to disclose.
Wendy Sherman, MD	Dr. Sherman has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Focused ultrasound foundation . Dr. Sherman has received personal compensation in the range of $500-$4,999 for serving as a Advisory Board Member with Kiyatec.